Rezolute announced expanded analyses from its Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism patients, showing significant and consistent glycemic improvements via continuous glucose monitoring compared to placebo. Although the primary endpoint was not met, the study demonstrated clinically relevant reductions in hypoglycemia and increased blood glucose levels during maintenance dosing and in an ongoing open-label extension phase. The FDA acknowledged challenges with the primary endpoint and requested broader data for evaluation, with Rezolute optimistic about advancing the program toward approval. These results highlight ersodetug's potential to transform treatment for congenital hyperinsulinism.
Bitcoin's recent price action resembles a bearish pattern from 2022, where a second, deeper drop followed an initial decline. The cryptocurrency has fallen below its 200-day moving average and formed a bear flag, signaling potential further downside ...
SpaceX, led by Elon Musk, is preparing for an IPO with a valuation target of $1.75 trillion. Financial data firms S&P Global and MSCI will determine which sector SpaceX fits into, considering its diverse business areas including space launches, satel...
Ethereum's leveraged bullish positions are increasing despite weakening spot market demand and resistance near $2,150-$2,200. Institutional outflows and rising macroeconomic pressures, including higher Treasury yields and dollar strength, are limitin...
At Google Next 2026, Google Cloud Security used Instruqt's hands-on platform to train over 150 practitioners on Agentic AI capabilities. Participants built their own AI agents in dedicated Google Cloud Vertex AI environments, gaining practical experi...
Tom Lee's Ethereum holdings show nearly $7.35 billion in unrealized losses, reflecting a significant drop from his acquisition cost. This large paper loss highlights the current bearish sentiment in the crypto market, influenced by regulatory uncerta...
